Wnt/β‐catenin signalling pathway is required for FDPS‐mediated CCL20 induction. A, mRNA level of CCL20 in the conditional medium from A172 FDPS‐overexpressing cells with or without XAV‐939 pre‐treatment was analysed by real‐time PCR. B, mRNA level of CCL20 in the conditional medium from H4 FDPS‐overexpressing cells with or without XAV‐939 pre‐treatment was analysed by real‐time PCR. C, The level of CCL20 in the conditional medium from A172 FDPS‐overexpressing cells with or without XAV‐939 pre‐treatment was analysed by ELISA. D, The level of CCL20 in the conditional medium from H4 FDPS‐overexpressing cells with or without XAV‐939 pre‐treatment was analysed by ELISA. E, The level of CCL20 in the conditional medium from U87 FDPS knockdown cells with or without β‐catenin overexpression was analysed by ELISA. F, The level of CCL20 in the conditional medium from U251 FDPS knockdown cells with or without β‐catenin overexpression was analysed by ELISA. G, CCL20 was analysed by IHC in the shcon and shFDPS U87 tumours. H, CCL20 was analysed by IHC in the vector and FDPS GL261 tumours. I, p‐β‐catenin was analysed by IHC in the shcon and shFDPS U87 tumours. J, p‐β‐catenin was analysed by IHC in the vector and FDPS GL261 tumours. K, Volume of parental and FDPS‐overexpressing GL261 tumours treated as indicated. L, F4/80+ cells in sections from indicated glioma tumours. Error bars represent the SD, *P < 0.05; **P < 0.01